3-(2,2-dicyanovinyl)benzoic acid | 61471-44-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2,2-dicyanovinyl)benzoic acid
• 英文别名: 3-Carboxybenzylidenmalonitril；3-(2,2-Dicyanoethenyl)benzoic acid
• CAS: 61471-44-1
• 化学式: C₁₁H₆N₂O₂
• mdl: MFCD06213984
• 分子量: 198.181
• InChiKey: YSNHHQSTWHFNGV-UHFFFAOYSA-N

物化性质

• 沸点：
  438.5±35.0 °C(Predicted)
• 密度：
  1.357±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-羧基苯甲醛 、 丙二腈 在 L-脯氨酸 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以15%的产率得到3-(2,2-dicyanovinyl)benzoic acid
  参考文献：
  名称：

  Cinnamonitrile Adjuvants Restore Susceptibility to β-Lactams against Methicillin-Resistant Staphylococcus aureus

  摘要：

  beta-Lactams are used routinely to treat Staphylococcus aureus infections. However, the emergence of methicillin-resistant S. aureus (MRSA) renders them clinically precarious. We describe a class of cinnamonitrile adjuvants that restore the activity of oxacillin (a penicillin member of the beta-lactams) against MRSA. The lead adjuvants were tested against six important strains of MRSA, one vancomycin-intermediate S. aureus (VISA) strain, and one linezolid-resistant S. aureus strain. Five compounds out of 84 total compounds showed broad potentiation. At 8 mu M (E)-3-(5-(3,4-dichlorobenzy1)-2-(trifluoromethoxy)phenyl)-2-(methylsulfonyl)acrylonitrile (26) potentiated oxacillin with a >4000-fold reduction of its MIC (from 256 to 0.06 mg.L-1). This class of adjuvants holds promise for reversal of the resistance phenotype of MRSA.

  DOI：

  10.1021/acsmedchemlett.9b00169

文献信息

• COPOLYMER AND OPTICAL FILM USING SAME
  申请人：Tosoh Corporation

  公开号：EP3553097A1

  公开（公告）日：2019-10-16

  Provided are a novel copolymer which is expected to form an optical film that has excellent retardation characteristics such as high retardation even in a thin film and an optical film using the same. A copolymer comprising a residue unit A represented by the general formula (1) and a residue unit B represented by the general formula (2): wherein R1 and R2 each independently represent hydrogen (provided that the case where R1 and R2 are both hydrogen is eliminated), a cyano group, an ester group (-C(=O)OX1), an amide group (-C(=O)N(X2)(X3)), or an acyl group (-C(=O)X4) (where X1 to X3 each independently represent a linear alkyl group having 1 to 12 carbon atoms, a branched alkyl group having 1 to 12 carbon atoms, or a cyclic alkyl group having 3 to 6 carbon atoms, and X4 represents a linear alkyl group having 1 to 12 carbon atoms, a branched alkyl group having 1 to 12 carbon atoms, or a cyclic group having 3 to 14 carbon atoms); R3 to R7 each independently represent hydrogen, a linear alkyl group having 1 to 12 carbon atoms, a branched alkyl group having 1 to 12 carbon atoms, a cyclic group having 3 to 14 carbon atoms, a halogen, a hydroxy group, a carboxy group, a nitro group, a cyano group, an alkoxy group (-OX5), an ester group (-C(=O)OX6), an amide group (-C(=O)N(X7)(X8)), an acyl group (-C(=O)X9), an amino group (-N(X10)(X11)), or a sulfonic acid group (-SOOX12) (where X5 to X8 each independently represent a linear alkyl group having 1 to 12 carbon atoms, a branched alkyl group having 1 to 12 carbon atoms, or a cyclic alkyl group having 3 to 6 carbon atoms, X9 to X12 each independently represent hydrogen, a linear alkyl group having 1 to 12 carbon atoms, a branched alkyl group having 1 to 12 carbon atoms, or a cyclic alkyl group having 3 to 6 carbon atoms); and adjacent substituents among R3 to R7 may form a fused ring structure each other, wherein R8 represents an m-membered heterocyclic residue containing one or more heteroatoms or a 5-membered or 6-membered ring residue containing no heteroatom (provided that, when R8 is a 6-membered ring residue containing no heteroatom, at least one of R3 to R7 in the general formula (1) represents a hydroxy group), and m represents an integer of 5 to 10; and the m-membered heterocyclic residue, the 5-membered ring residue, and the 6-membered ring residue may form a fused ring structure.

  本发明提供了一种新型共聚物，该共聚物可望形成一种光学薄膜，该光学薄膜具有优异的延缓特性，例如即使在薄膜中也具有高延缓性，本发明还提供了使用该共聚物的光学薄膜。 由通式（1）表示的残留单元 A 和通式（2）表示的残留单元 B 组成的共聚物： 其中 R1 和 R2 各自独立地代表氢（前提是排除 R1 和 R2 都是氢的情况）、氰基、酯基（-C(＝O)OX1）、酰胺基（-C(＝O)N(X2)(X3)）或酰基（-C(＝O)X4）（其中 X1 至 X3 各自独立地代表具有 1 至 12 个碳原子的直链烷基、具有 1 至 12 个碳原子的支链烷基或具有 3 至 6 个碳原子的环状烷基，而 X4 代表具有 1 至 12 个碳原子的直链烷基、具有 1 至 12 个碳原子的支链烷基或具有 3 至 14 个碳原子的环状基团）；R3 至 R7 各自独立地代表氢、具有 1 至 12 个碳原子的直链烷基、具有 1 至 12 个碳原子的支链烷基、具有 3 至 14 个碳原子的环基、卤素羟基、羧基、硝基、氰基、烷氧基 (-OX5)、酯基 (-C(=O)OX6)、酰胺基 (-C(=O)N(X7)(X8))、酰基 (-C(=O)X9)、氨基 (-N(X10)(X11))、或磺酸基（-SOOX12）（其中 X5 至 X8 各自独立地代表具有 1 至 12 个碳原子的直链烷基、具有 1 至 12 个碳原子的支链烷基或具有 3 至 6 个碳原子的环状烷基，X9 至 X12 各自独立地代表氢、具有 1 至 12 个碳原子的直链烷基、具有 1 至 12 个碳原子的支链烷基或具有 3 至 6 个碳原子的环状烷基）；R3 至 R7 中的相邻取代基可相互形成融合环结构、 其中 R8 代表含有一个或多个杂原子的 m 元杂环残基或不含杂原子的 5 元或 6 元环残基（条件是，当 R8 是不含杂原子的 6 元环残基时，通式（1）中 R3 至 R7 中至少有一个代表羟基），且 m 代表 5 至 10 的整数；且 m 元杂环残基、5 元环残基和 6 元环残基可形成融合环结构。
• Copolymer and optical film using same
  申请人：TOSOH CORPORATION

  公开号：US11225540B2

  公开（公告）日：2022-01-18

  A novel copolymer suitable for an optical film which is excellent in optical characteristics and has high retardation even in a thin film state, and an optical film containing the same are provided. A copolymer excellent in optical characteristics and easy to form a composite with a different polymer, and an optical film composed of the same are also provided.

  本发明提供了一种适用于光学薄膜的新型共聚物，这种共聚物具有优异的光学特性，即使在薄膜状态下也具有较高的延缓性，本发明还提供了一种含有这种共聚物的光学薄膜。此外，还提供了一种光学特性优异且易于与其他聚合物形成复合材料的共聚物，以及由其构成的光学薄膜。
• Cinnamonitrile Adjuvants Restore Susceptibility to β-Lactams against Methicillin-Resistant <i>Staphylococcus aureus</i>
  作者：Enrico Speri、Choon Kim、Stefania De Benedetti、Yuanyuan Qian、Elena Lastochkin、Jennifer Fishovitz、Jed F. Fisher、Shahriar Mobashery

  DOI：10.1021/acsmedchemlett.9b00169

  日期：2019.8.8

  beta-Lactams are used routinely to treat Staphylococcus aureus infections. However, the emergence of methicillin-resistant S. aureus (MRSA) renders them clinically precarious. We describe a class of cinnamonitrile adjuvants that restore the activity of oxacillin (a penicillin member of the beta-lactams) against MRSA. The lead adjuvants were tested against six important strains of MRSA, one vancomycin-intermediate S. aureus (VISA) strain, and one linezolid-resistant S. aureus strain. Five compounds out of 84 total compounds showed broad potentiation. At 8 mu M (E)-3-(5-(3,4-dichlorobenzy1)-2-(trifluoromethoxy)phenyl)-2-(methylsulfonyl)acrylonitrile (26) potentiated oxacillin with a >4000-fold reduction of its MIC (from 256 to 0.06 mg.L-1). This class of adjuvants holds promise for reversal of the resistance phenotype of MRSA.